Immunotherapy company Argos Therapeutics has developed a new technology that could set it apart from other biotechnology cancer treatments — an approach that’s completely personalized to the patient ...
Therakos will use it to enhance treatments against immune-mediated diseases. Argos Therapeutics signed an exclusive licensing agreement with Therakos, a Johnson & Johnson company, for the research and ...
Lummy HK Obtains Rights to Manufacture, Develop and Commercialize AGS-003 in China, Hong Kong, Taiwan, and Macau DURHAM, N.C., April 14, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS) ...
DURHAM, N.C. -- Nov 16, 2007 - Argos Therapeutics announced today that it has granted Therakos, Inc., a Johnson & Johnson company, an exclusive license for the research and development of novel ...
M&A is a massive part of today’s retail landscape; and in the UK this hasn’t got much bigger than Sainsbury’s 2016 takeover of Argos’ parent company Home Retail Group. RetailTechNews caught up with ...
Argos Therapeutics, Inc. has announced that it is partnering with Adaptive Biotechnologies Corporation to study precise response patterns to Argos' investigational immunotherapies. Under the agreement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback